Abstract
Do estrogen and Wnt/β-catenin signaling promote vascular endothelial growth factor (VEGF) expression in endometriosis and how? 17β-Estradiol (E2)-drives β-catenin triggered up-regulation of VEGF in effector human primary endometrial stromal cells (ESCs) and thus enhances their ability to establish a new blood supply to the human exfoliated endometrium. Implantation and survival of exfoliated endometrium is crucially dependent on neovascularization and Wnt/β-catenin signaling plays an important role in stimulating angiogenesis. Expression levels of VEGF mRNA, estrogen receptor α (ERα) and β-catenin protein were measured in ovarian endometriosis, eutopic endometrium of endometriosis patients and normal endometrium with real-time RT-PCR and western blot. ESCs were treated with 10 nM E2 for different times in order to evaluate the effect of E2 on ERα, β-catenin and VEGF expression in these cells. Human endometrial stromal cells (T HESCs) were cultured for transfection with expression vectors and siRNA constructs and used in chromatin immunoprecipitation (ChIP) and luciferase assays, which were conducted to clarify the regulation mechanism of E2 on VEGF. VEGF, ERα and β-catenin expression was increased in endometriotic lesions compared with normal endometrium. E2 could promote ERα, β-catenin and VEGF expression in ESCs. ChIP and luciferase assays revealed that E2 up-regulated β-catenin expression by binding to the estrogen response element site on the β-catenin promoter. β-Catenin stabilization could activate Wnt/β-catenin signaling, which has a direct transcriptional effect on VEGF gene expression. Endometriotic lesions were all from ovarian endometriosis and may differ from other type of endometriosis. These promising results improve the body of knowledge on endometriosis pathogenesis and could open up new therapeutic strategies for the treatment of endometriosis. This project was supported by the National Natural Science Foundation of China (grant no. 81170545 Y.L. and 81471439 Y.L.). None of the authors has any conflicting interests to declare.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.